beat view better revenu profit factor
line ad lower ep
reflect higher tax rate interest expens importantli
make meaning chang oper assumpt note
top-line profit guidanc assumpt consist januari
revenu upsid acquisit contribut profit ahead revenu
growth well view driven contribut
acquisit million impli organ revenu declin
continu hepat weak profit match expect
ebitda margin rise bp yoy help higher margin acq
contribut favor broader product mix dplo gener
million cash vs million help facilit
acquisit np ldi well earli de-lever effort ttm pro
forma net leverag stand estim
reiter neutral reaffirm oper guidanc
fairli in-lin quarter view today result rel non-ev
would note recent pbm acquisit expect add million
revenu impli revenu growth excl npi ld
midpoint estimate core organ view encourag given
meaning improv compar estim organ revenu declin
look ahead focu turn execut new pbm
strategi associ integr help mitig slow organ
growth profil competit specialti pharmaci sector outlin
recent upgrad note see compel pbm opportun continu view
dplo recent ldi np acquisit offer new avenu growth
compel revenu cost synergi diversifi scope
offer risk includ shift fundament demand reimburs
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
diplomat pharmaci independ specialti pharmaci
dispens pharmaceut patient complex chronic
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario predic acceler
integr recent acquir pbm accompani earlier
expect execut cost synergi cross-sel
acceler de-lever allow dplo resum acquisit
strategi earlier expect strategi mind potenti
diversifi suppli chain acquir could like
grey sky scenario predic unexpect
slowdown specialti pharmaceut industri
regulatory/reimburs shift integr miscu
 close
dplo post organ revenu growth exclud acquisit contribut
million quarter reflect continu weak relat hepat
contract termin perform repres slight improv
estim declin hepat account less revenu
quarter volum appear stabil dynam dplo like continu
lap throughout balanc along contract shift
importantli dplo unveil ep guidanc vs consensu
reflect higher interest expens tax rate assumpt importantli
chang oper target pre-announce see note
exclud million estim revenu contribut recent acquir pbm
ldi np well commun focu rx revenu
contribut disclos revenu guidanc impli core organ growth roughli
guid also impli ebitda margin expans bp help higher
margin contribut ldi np stabl gross margin trend core specialti
pharmaci busi well expect realiz roughli million
acquisit cost synergi expect commenc
figur dplo organ acquir revenu
estim revenu acquisit
compani data credit suiss estim dollar million
flow improv significantli yoy compani gener million cash
quarter vs cash burn million ttm cash convers cycl
decreas day day slightli better dpo experi importantli
relat capit deploy focu near term de-lever compani
target net leverag ratio estim dplo ttm pro
forma net leverag ratio current stand ebitda model current
emb roughli million de-lever
broadli expect dplo begin realiz benefit diversifi
differenti pharmaci solut follow recent pbm
transact notabl shift strategi compani new pbm focu repres
logic evolut view help drive new busi win may
disadvantag comprehens pbm offer
evidenc recent contract loss past year still leverag uniqu
access product limit distribut drug panel specialti infus offer
manufactur servic comprehens pbm solut offer new
avenu growth view
longer term follow near term focu de-lever expect
clear path dplo continu scale pbm offer longer term
continu manag previous note capit deploy form
pbm acquisit product use capit move forward supplement
cross-sel opportun across current custom base initi synergi
recent pbm deal materi meaning beyond
figur anticip specialti pharmaci pipelin
expect specialti pharmaci launch
rout administr
phase studi
note interim ceo jeff park held command presenc today confer
call dplo provid updat perman replac recent retir
co-found phil hagerman see note time jeff park former cfo
catamaran optumrx continu serv interim ceo
compani hold preconceiv notion view interim ceo jeff park like
frontrunn perman role given extens experi consolid
pbm space catamaran well role broker ultim sale
provid detail jeff park background
prior appoint park member dplo board director sinc june
park first join member board director becam
cfo park help overse merger catalyst health
solut later rebrand combin entiti catamaran cfo park help
transform scale catamaran larg pbm organ
np ldi catamaran acquisit park helm includ catalyst health
million feb ptrx million oct among other
catamaran acquir transact valu billion
ltm ebitda fold exist optumrx platform park assum
role follow close acquisit
earn outlook valuat
forecast revenu grow larg driven contribut recent
acquir pbm ldi np total estim million full year
forecast ebitda margin expans bp help higher margin
contribut recent acquisit lead ep yoy increas
charl martineau pm univers toronto forecast revenu grow forecast ebitda margin degrad
bp ep grow help expect focu
de-lever cours
acro pharmaceut servic commun pharmaci servic
vantag oncolog biolog inc
compani mention price
